当前位置: X-MOL 学术Drug. Discov. Today › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Recent progress in antitumor functions of the intracellular antibodies.
Drug Discovery Today ( IF 7.4 ) Pub Date : 2020-02-26 , DOI: 10.1016/j.drudis.2020.02.009
Yunfeng Lin 1 , Zhuo Chen 2 , Chaohua Hu 3 , Zhe-Sheng Chen 4 , Lei Zhang 2
Affiliation  

Conventional antibodies used for cancer therapies can only target the extracellular epitopes of tumor-associated antigens (TAAs); however, they struggle to enter cancer cells to interact with intracellular TAAs. Intrabodies are the engineered single-chain antibodies that can be transferred to the living cells or expressed within the cells and target the intracellular TAAs, owing to their nanosizes, enhanced motility and specific and potent binding affinities for the TAAs. Intrabody-based technology is a supplement to the current gene silencing technologies that can regulate a variety of biochemical processes and cellular functions and could be applicable for clinical treatment of tumors. Here, we review the development and current status of the intrabodies for the targeted treatment of cancers.



中文翻译:

细胞内抗体抗肿瘤功能的最新进展。

用于癌症治疗的常规抗体只能针对肿瘤相关抗原(TAA)的细胞外表位;然而,它们很难进入癌细胞与细胞内 TAA 相互作用。Intrabodies 是工程化的单链抗体,由于它们的纳米尺寸、增强的运动性以及对 TAA 的特异性和有效结合亲和力,可以转移到活细胞或在细胞内表达并靶向细胞内 TAA。基于体内的技术是对现有基因沉默技术的补充,可以调节多种生化过程和细胞功能,可用于肿瘤的临床治疗。在这里,我们回顾了用于癌症靶向治疗的体内抗体的发展和现状。

更新日期:2020-02-26
down
wechat
bug